The trial is taking place at:
M

Manhattan Medical Research | New York, NY

Veeva-enabled site

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Vanda Pharmaceuticals logo

Vanda Pharmaceuticals

Status and phase

Enrolling
Phase 3

Conditions

Motion Sickness

Treatments

Drug: Placebo
Drug: Tradipitant

Study type

Interventional

Funder types

Industry

Identifiers

NCT05903924
VP-VLY-686-3404

Details and patient eligibility

About

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Enrollment

300 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* History of motion sickness * Age 18-75

Exclusion criteria

* Nausea-inducing disorder other than motion sickness * BMI\>40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

300 participants in 3 patient groups, including a placebo group

Tradipitant High Dose
Experimental group
Treatment:
Drug: Tradipitant
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
Tradipitant Low Dose
Experimental group
Treatment:
Drug: Tradipitant

Trial contacts and locations

5

Loading...

Central trial contact

Vanda Pharmaceuticals

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems